Clinical Trials

Seattle Children's Hospital Trial
More information...


( identifier: NCT02728401)

2013 – present: The Genotypes and Phenotypes in Pediatric SIRS and Sepsis (GAPPSS) trial is a collaborative pilot study at the Seattle Children’s Hospital between Professor Jerry Zimmerman and Immunexpress. Immunexpress and the Seattle Children’s Research Institute are jointly funding this study.

Ward Study
More information...


( identifier: NCT02704871)

2013-2017: The Ward Study for SeptiCyteTM Lab to Distinguish Between Infection-positive and Infection-negative SIRS is a non-interventional, prospective observational study to assess the performance of SeptiCyteTM Lab to diagnose patients identified as suspected of sepsis in general medical and surgical wards with infection-positive from infection-negative SIRS.

More information...


( identifier: NCT02127502)

2014 – 2016: The Validation of septic gene ExpressioN Using SeptiCyte (VENUS) trial commenced in May 2014 at two Intermountain Healthcare clinical sites: the Intermountain Medical Center in Murray, UT and the Latter Day Saints hospital in Salt Lake City, UT, USA. It later expanded to five additional hospitals: Johns Hopkins Hospital in Baltimore, MD; Northwell Health in Manhasset, NY; Emory Healthcare in Atlanta GA; Loyola University Medical Center in Maywood, IL; and Rush University Medical Center in Chicago, IL. It was a prospective observational cohort study of approximately 300 ICU patients.

MARS Sepsis Consortium Trial
More information...


( identifier: NCT01905033)

2011 – 2014: The MARS Sepsis Consortium trial is a prospective observational cohort study designed to produce molecular information relevant to sepsis diagnosis and management. Immunexpress is a full partner in the collaborative Consortium. The Consortium recruited 7,398 critical care patients with signs of Systemic Inflammatory Response Syndrome (SIRS) across two tertiary hospitals in the Netherlands: the Academisch Medisch Centrum in Amsterdam, and the University Medical Centre Utrecht (UMCU). Immunexpress is continuing collaborative sepsis clinical research at both study sites.

University College London Hospital Trials
More information...


2011 – present: University College London and Immunexpress continue to collaborate in prospective observational cohort studies – Sepsis: Pathophysiological and Organizational Timing clinical trials.  These longitudinal studies include septic pneumonia and immunocompromised sepsis patients.

Classifier Discovery Trials
More information...


2007 – 2011: Clinical trials across four tertiary care settings in Brisbane, Queensland (Australian New Zealand Clinical Trial Registry identified ACTRN12610000465055; Australian Department of Health and Aging CTN Number 044/2008): Wesley Hospital, Mater Health Services, Princess Alexandra Hospital and the Royal Brisbane & Women’s Hospital.